When Neuropathy Patients Are Still in Pain: Is Your Treatment Pathway Giving You Enough Options?

For podiatrists treating peripheral neuropathy, one of the most challenging conversations is not with a newly diagnosed patient.

It is with the patient who has already been evaluated, diagnosed, and treated—and is still experiencing burning, tingling, shooting pain, or persistent discomfort.

You know the patient.

They have followed the recommended treatment plan. They have returned for follow-up visits. Their medications may have been adjusted, their underlying conditions addressed, and their progress monitored.

Yet the symptoms remain.

And eventually, the question comes:

“Doctor, what else can we try?”

For an established podiatry practice, that question deserves more than another discussion of the same options. It invites a closer look at whether the existing neuropathy treatment pathway offers enough flexibility for patients whose symptoms remain difficult to manage.

When the Diagnosis Is Clear, but the Results Are Limited

Peripheral neuropathy is not unfamiliar territory for podiatrists.

We recognize the clinical presentations, understand the contributing conditions, and routinely evaluate the sensory and functional changes associated with peripheral nerve dysfunction.

The challenge is not always identifying the condition.

Sometimes, it is determining the next appropriate step when the patient has not achieved meaningful improvement.

Established treatment approaches remain important. Medication management, metabolic risk-factor control, foot protection, appropriate footwear, physical therapy, and other interventions each have a place depending on the patient's presentation.

But even with appropriate care, some patients continue to experience symptoms that interfere with sleep, daily activities, and quality of life.

The American Academy of Neurology's guidance for painful diabetic neuropathy acknowledges that treatment goals often involve reducing pain rather than eliminating it entirely. It also recommends reassessing treatment when meaningful improvement is not achieved.

For providers, this reinforces an important clinical reality:

A treatment can be appropriate without being sufficient for every patient.

The Difference Between Managing Symptoms and Expanding Treatment Options

When patients continue to report neuropathic pain, the response should not automatically be to abandon the treatment plan.

It may be time to evaluate what the current plan is accomplishing—and where additional options could fit.

Consider the patient whose nighttime burning has improved but remains disruptive.

Or the patient whose medication provides some relief but creates tolerability concerns.

Or the patient who continues to experience intermittent shooting pain despite ongoing management of contributing conditions.

These situations are familiar in neuropathy care.

They also raise practical questions:

• Are we measuring meaningful changes in pain, sleep, and daily function?

• Have we reassessed the diagnosis, contributing conditions, and treatment response?

• Are adverse effects or treatment burden limiting progress?

• Would an additional treatment modality be appropriate for this patient?

These are not questions about replacing established care.

They are questions about making the care pathway more responsive.

Patients Are Looking for Progress, Not Just Another Prescription

For many patients, the impact of neuropathy extends well beyond the symptoms documented during an office visit.

Burning feet can interrupt sleep.

Shooting pain can make routine activity unpredictable.

Persistent discomfort can affect concentration, mobility, and willingness to remain active.

And when treatment response is limited, patients may begin to question whether additional improvement is possible.

This is where communication becomes as important as clinical decision-making.

Patients need realistic expectations, an explanation of what their current treatment is intended to accomplish, and a clear understanding of what may come next.

A structured neuropathy program can support that conversation by establishing consistent evaluation, patient education, treatment monitoring, and follow-up.

It also helps the practice distinguish between patients who are responding adequately and those who may benefit from further assessment or additional treatment considerations.

Why More Treatment Options Matter in an Established Podiatry Practice

For a podiatrist already treating neuropathy, adding another modality should serve a clear purpose.

The question is not whether the practice can offer something new.

It is whether the additional option complements the care already being delivered.

A meaningful addition should support appropriate patient selection, fit the existing clinical workflow, provide a structured treatment approach, and offer a practical way to monitor patient response.

It should also come with the training and operational resources necessary for consistent implementation.

Because acquiring technology is only one part of expanding a treatment program.

The larger consideration is how that technology becomes part of the practice's clinical process.

The goal is not more treatment for the sake of more treatment. It is a more complete set of options for patients whose needs are not being fully addressed.

Where Neurogenx Fits Into the Neuropathy Treatment Pathway

Neurogenx was developed to give providers an additional approach to managing neuropathy and chronic nerve-related symptoms.

Using the Neurogenx 4000PRO system with NervePro 2.0, Electronic Signal Treatment (EST) delivers a sophisticated electronic signal through strategically positioned electrodes as part of a clinician-directed treatment plan.

The system uses FDA-cleared medical-device technology and provides a non-invasive, non-narcotic treatment option for appropriately selected patients.

For podiatrists, the opportunity is to consider how EST may complement an established neuropathy program—not replace the diagnostic evaluation, underlying disease management, medications, rehabilitation, or other care patients may require.

Importantly, the clinical evidence supporting a particular treatment should be evaluated separately from its proposed mechanism of action. The use of FDA-cleared technology does not, by itself, establish nerve regeneration or improved outcomes for every patient.

Beyond the technology, Neurogenx provides clinical protocols, provider and staff education, implementation resources, and continuing support through its PLUS Programs.

This combination is intended to help practices integrate the treatment into existing operations rather than build a new service line without guidance.

The Next Step in Neuropathy Care May Be Expanding What You Can Offer

For established podiatrists, neuropathy care is rarely a question of recognizing the symptoms.

The harder question is what to do when patients continue to experience them despite appropriate treatment.

Not every patient will need another modality. Not every patient will be a candidate for the same approach.

But having a broader, clinically responsible treatment pathway can make those conversations more productive.

It allows the practice to move beyond repeating what has already been tried and toward evaluating what else may be appropriate.

When a patient asks, “What else can we try?” the answer should begin with a thoughtful clinical reassessment—and an understanding of the options available.

Explore Another Option for Your Neuropathy Program

If your practice already treats peripheral neuropathy but continues to see patients struggling with persistent nerve-related symptoms, Neurogenx may be worth evaluating as an additional component of your existing care pathway.

Discover how the Neurogenx 4000PRO and PLUS Programs can support your practice with treatment technology, clinical training, implementation resources, and ongoing support.